Technical Analysis for GRCL - Gracell Biotechnologies Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Flat |
| Historical GRCL trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.65% | |
| Bollinger Band Squeeze | Range Contraction | 0.65% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 0.65% | |
| BB Squeeze Started | Range Contraction | 0.65% | |
| Outside Day | Range Expansion | 0.65% | |
| Lower Bollinger Band Touch | Weakness | 0.65% | |
| 20 DMA Resistance | Bearish | 4.10% | |
| Pocket Pivot | Bullish Swing Setup | 4.10% | |
| Outside Day | Range Expansion | 4.10% | |
| Fell Below 20 DMA | Bearish | -3.06% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Possible NR7 | about 3 hours ago |
| Gap Up Partially Closed | about 6 hours ago |
| 10 DMA Resistance | about 6 hours ago |
| 10 DMA Support | about 6 hours ago |
| Gapped Up (Full) | about 6 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Solid Tumors Immune System Health Sciences Cancer Immunotherapy Lymphoma Gene Therapy Chimeric Antigen Receptor T Cell
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Solid Tumors Immune System Health Sciences Cancer Immunotherapy Lymphoma Gene Therapy Chimeric Antigen Receptor T Cell
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 33.6999 |
| 52 Week Low | 9.75 |
| Average Volume | 162,415 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 13.30 |
| 20-Day Moving Average | 11.66 |
| 10-Day Moving Average | 11.50 |
| Average True Range | 0.98 |
| ADX | 18.81 |
| +DI | 17.09 |
| -DI | 21.02 |
| Chandelier Exit (Long, 3 ATRs) | 10.50 |
| Chandelier Exit (Short, 3 ATRs) | 13.46 |
| Upper Bollinger Bands | 12.70 |
| Lower Bollinger Band | 10.62 |
| Percent B (%b) | 0.41 |
| BandWidth | 17.90 |
| MACD Line | -0.47 |
| MACD Signal Line | -0.52 |
| MACD Histogram | 0.0547 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 13.91 | ||||
| Resistance 3 (R3) | 13.85 | 12.99 | 13.50 | ||
| Resistance 2 (R2) | 12.99 | 12.37 | 13.02 | 13.37 | |
| Resistance 1 (R1) | 12.24 | 11.99 | 12.61 | 12.29 | 13.23 |
| Pivot Point | 11.37 | 11.37 | 11.56 | 11.40 | 11.37 |
| Support 1 (S1) | 10.62 | 10.76 | 11.00 | 10.67 | 9.73 |
| Support 2 (S2) | 9.76 | 10.37 | 9.78 | 9.59 | |
| Support 3 (S3) | 9.00 | 9.76 | 9.46 | ||
| Support 4 (S4) | 9.05 |
